Considering that methylation is potentially reversible, detection of those aberrant methylated MDGs, including ANKRD10, BMP2, LOXL1, RPL39L, TMEM52, and VILL, may become potential molecular therapeutic targets for the treatment of GBM. This evidence concerns the gene RPL39L and glioblastoma.